Clinical Research Directory
Browse clinical research sites, groups, and studies.
N-Acetylcysteine in Patients With Leptospirosis
Sponsor: Dr Cipto Mangunkusumo General Hospital
Summary
The goal of this clinical trial is to learn whether oral N-acetylcysteine (NAC) can reduce markers of kidney tubular injury, oxidative stress, and inflammation in adults with non-severe leptospirosis. The main questions it aims to answer are: * Does NAC result in a greater reduction in urinary kidney injury molecule-1 (KIM-1) levels from Day 1 to Day 5 compared with placebo? * Does NAC result in a greater reduction in serum reactive oxygen species (ROS) and C-reactive protein (CRP) levels from Day 1 to Day 5 compared with placebo? Researchers will compare NAC with a placebo to determine whether NAC produces greater changes in these biomarkers. Participants will: * Receive oral NAC 800 mg three times daily or a matching placebo for five days in addition to standard treatment for leptospirosis. * Have urinary KIM-1, serum ROS, and CRP measured before treatment and on Day 5.
Official title: Efek N-Acetylcysteine Terhadap Cedera Tubulus Ginjal, Stres Oksidatif, Dan Inflamasi Pada Pasien Leptospirosis Non-Severe: Sebuah Uji Klinis Acak Tersamar Ganda
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2025-08-30
Completion Date
2026-04-26
Last Updated
2026-09-16
Healthy Volunteers
No
Conditions
Interventions
N-acetylcysteine
Participants received oral N-acetylcysteine 800 mg three times daily for 5 consecutive days.
Placebo
Participants received an oral matching placebo three times daily for 5 consecutive days.
Locations (1)
RSUD Balaraja
Tangerang, Banten, Indonesia